Shopping Cart
- Remove All
- Your shopping cart is currently empty
RWJ-67657 (JNJ 3026582) is an orally active, selective p38α and p38β MAPK inhibitor (IC50s: 1 and 11 μM, respectively), with no activity at p38γ and p38δ, and demonstrates cardioprotective effects.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | 37 € | In Stock | |
5 mg | 60 € | In Stock | |
10 mg | 92 € | In Stock | |
25 mg | 216 € | In Stock | |
50 mg | 349 € | In Stock | |
100 mg | 563 € | In Stock | |
500 mg | 1.187 € | In Stock | |
1 mL x 10 mM (in DMSO) | 66 € | In Stock |
Description | RWJ-67657 (JNJ 3026582) is an orally active, selective p38α and p38β MAPK inhibitor (IC50s: 1 and 11 μM, respectively), with no activity at p38γ and p38δ, and demonstrates cardioprotective effects. |
Targets&IC50 | p38α:1 μM, p38β:11 μM |
In vitro | RWJ-67657 suppresses the release of TNF-α by lipopolysaccharide (LPS)-treated human peripheral blood mononuclear cells (IC50: 3 nM) and the release of TNF-α from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B (IC50: 13 nM). RWJ67657 (10 μM; 24 hours) reduces colony formation in MCF-7 cells [2][3]. |
In vivo | RWJ-67657 inhibits TNF-alpha production in lipopolysaccharide-injected mice (87% inhibition at 50 mg/kg) and in rats (91% inhibition at 25 mg/kg) after oral administration. RWJ-67657 (50 mg/kg; p.o.; once daily for 7 consecutive days) demonstrates effective anti-inflammatory activity. EPC transplantation combined with RWJ-67657 administration synergistically promotes angiogenesis and neurogenesis following diabetic stroke by enhancing endothelial progenitor cell function and reducing inflammation [2][4]. |
Alias | JNJ 3026582 |
Molecular Weight | 425.5 |
Formula | C27H24FN3O |
Cas No. | 215303-72-3 |
Smiles | OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1 |
Relative Density. | 1.14 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 125 mg/mL (293.77 mM), Sonication and heating to 60℃ are recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.